A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Yale University
National Cancer Institute (NCI)
Medical College of Wisconsin
SWOG Cancer Research Network
Baylor Research Institute
Alliance for Clinical Trials in Oncology
Roswell Park Cancer Institute
NRG Oncology
Mayo Clinic
SN BioScience
IMGT Co., Ltd.
Medical College of Wisconsin
National Health Research Institutes, Taiwan
Taiho Oncology, Inc.
University of Kentucky
Revolution Medicines, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Massachusetts General Hospital
National Cancer Institute (NCI)
Thomas Jefferson University
Bristol-Myers Squibb
University of Nebraska
University of Cincinnati
CARsgen Therapeutics Co., Ltd.
Second Affiliated Hospital, School of Medicine, Zhejiang University
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
CNAO National Center of Oncological Hadrontherapy
Ono Pharmaceutical Co. Ltd
Case Comprehensive Cancer Center
Emory University
Dana-Farber Cancer Institute
Akeso
Bruckner Oncology
Australasian Gastro-Intestinal Trials Group
Oslo University Hospital
Ono Pharmaceutical Co. Ltd
Actuate Therapeutics Inc.
Erasmus Medical Center
Rutgers, The State University of New Jersey
Seoul National University Hospital
OHSU Knight Cancer Institute
UNICANCER
Shanghai Zhongshan Hospital
Albert Einstein College of Medicine
Sumitomo Pharma America, Inc.
Changhai Hospital
Medical College of Wisconsin
Eastern Cooperative Oncology Group